

PathXL Expands its Workforce in the US

Don Ariyakumar and Timothy Baradet, Ph.D, join PathXL after major breakthrough into the US market.

BEL AIR, MD, USA, December 10, 2014 / EINPresswire.com/ -- PathXL announced today that Don Ariyakumar and Timothy Baradet, Ph.D., have joined the US Division of the company to support and further develop their growing portfolio of customers in the US market.



PathXL is a global pioneer in the use of web-based solutions for digital pathology.

Having recently gained three high profile clients, whom are among the 15 Top Cancer Centers in the US, both Don and Tim will work with John Durborow, Director of Sales and Business Development North America, to ensure that clients receive innovative products, combined with exceptional service.

Taking the role of Pre-Sales and Application Scientist, <u>Tim Baradet</u>, Ph.D. will be directly involved with both pre- and post-sales activities, providing installation, training, and technical support for PathXL clients in the US. Having spent most of his working career in pathology laboratories, Tim joins PathXL from the Digital Pathology Laboratory at the University Of Pennsylvania School Of Medicine, where he was Director for the last four years. Tim, who holds a Doctorate in Molecular Pathobiology, brings vast experience and industry knowledge to his role. He said:

"I am really looking forward to a new challenge and I can't wait to start traveling to meet and support PathXL clients, prospective clients and research partners."

Don Ariyakumar joins PathXL as Technical Sales Specialist. A core element of his role involves working with customers during the sales process, in order to assess and provide the best solutions for their requirements from the broad range of PathXL products. Don has a real passion for the industry and was instrumental in establishing a start-up biotech venture, of which he was principal. With both undergraduate and masters degrees in Biology, he went on to manage both the Ultrastructural Pathology Laboratory at the University of Minnesota, and the Nevada Cancer Program. Having been aware of PathXL for some time, Don stated:

"I feel really privileged to be part of such a respected company and I'm excited to work with the Team, the technology and the clients."

John Durborow, Director of Sales and Business Development North America said:

"Both Don and Tim's wealth of experience and unique knowledge make them key additions to the PathXL team. Our new innovations and the increasing demand from our customers led us to look at expanding our US team, and it is very fortunate that we were able to attract two individuals of such caliber to fulfil these roles. I look forward to working with both of these professionals, whom I am confident will play a key role in delivering quality solutions to our customers."

About PathXL

PathXL is a global pioneer in the use of web-based solutions for digital pathology, and provides innovative software for use in drug discovery research, clinical sectors, biomarker analysis and education. Their product for the automated identification and annotation of tumour tissue, TissueMark, was awarded the Frost and Sullivan 2014 European New Product Innovation Award for Automated Image Analysis for Digital Pathology. PathXL has just launched Xplore – a new application for image and data management, aiming to facilitate studies for Researchers worldwide.

Press release courtesy of Online PR Media: http://bit.ly/1wycZvK

John Durborow - Sales and Business Development Director PathXL 410.921.6974 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/239071252

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.